A neuroscientific update on monoamine oxidase and its inhibitors

CNS Spectrums

Volumn 18, Issue SUPPL.1, 2013, Pages 25-33

  Schwartz, Thomas L ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Antidepressant treatment; major depressive disorder; monoamine oxidase inhibition

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT;

BRAIN METABOLISM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MAJOR DEPRESSION; NEUROBIOLOGY; NEUROPSYCHIATRY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RISK FACTORS;

EID: 84890805455     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000734     Document Type: Review

References (46)

1. Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008; 358: 55-68.
3. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
4. Sadock BJ, Sadock VA, Sussman N. Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment, 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2011.
5. Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 4th ed. Cambridge, UK: Cambridge University Press; 2011.
6. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med. 2008; 40(2): 149-159.
7. Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry. 2001; 62(Suppl 22): 5-9.
8. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
9. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998; 44(5): 348-360.
10. Keller MB, Shapiro RW. "Double depression": superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry. 1982; 139(4): 438-442.
11. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am. 1996; 19(1): 85-102.
12. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STARD) study. Psychiatr Clin North Am. 2003; 26(2): 457-494; x.
13. Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep. 2012; 14(6): 643-649.
14. Schwartz TL, Stahl SM. Optimizing antidepressant management of depression: current status and future perspectives. In Cryan JF, Leonard BE, eds. Depression: From Psychopathology to Pharmacotherapy. Vol.
15. Basel, Switzerland: Karger; 2010: 54-67.
16. Sacher J, Rabiner EA, Clark M, et al. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. J Cereb Blood Flow Metab. 2012; 32(3): 443-446.
17. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009; 35(3): 549-562.
18. Du L, Faludi G, Pakovits M, et al. High activity-related allele of MAO-A gene associated with depressed suicide in males. Neuroreport. 2002; 13: 1195-1198.
19. De Luca V, Tharmalingam S, Sicard T, Kennedy JL. Gene-gene interaction between MAOA and COMT in suicidal behavior. Neurosci Lett. 2005; 383(1-2): 151-154.
20. Johnson S, Stockmeier CA, Meyer JH, et al. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology. 2011; 36(10): 2139-2148.
21. Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012; 91(2): 201-214.
22. Meyer JH, Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66(12): 1304-1312.
23. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006; 163(11): 1905-1917.
24. Zajecka JM, Goldstein C. Combining medications to achieve remission. In Schwartz TL, Petersen TJ, eds. Depression: Treatment Strategies and Management, 2nd Ed. New York: Informa; 2010; 54-100.
25. Pitychoutis PM, Zisaki A, Dalla C, Papadopoulou-Daifoti Z. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des. 2010; 16(20): 2214-2223.
26. Fan M, Liu B, Jiang T, et al. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr Genet. 2010; 20(1): 1-7.
27. Gutiérrez B, Arias B, Gastó C, et al. Association analysis between a functional polymorphism in the monoamine oxidase A gene promoter and severe mood disorders. Psychiatr Genet. 2004; 14(4): 203-208.
28. Kinnally EL, Huang YY, Haverly R, et al. Parental care moderates the influence of MAOA-uVNTR genotype and childhood stressors on trait impulsivity and aggression in adult women. Psychiatr Genet. 2009; 19(3): 126-133.
29. Lung FW, Tzeng DS, Huang MF, Lee MB. Association of the MAOA promoter uVNTR polymorphism with suicide attempts in patients with major depressive disorder. BMC Med Genet. 2011; 12: 74.
30. Schulze TG, Müller DJ, Krauss H, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet. 2000; 96(6): 801-803.
31. Xu Z, Zhang Z, Shi Y, et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord. 2011; 133(1-2): 165-173.
32. Buckholtz JW, Callicott JH, Kolachana B, et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry. 2008; 13(3): 313-324.
33. Schwartz TL. Psychopharmacological practice: the DSM versus the brain. Mens Sana Monogr. 2013; 11(1): 25-41.
34. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000; 157(1): 115-118.
35. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999; 19(12): 5034-5043.
36. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010; 67(4): 360-368.
37. Thalmeier A, Dickmann M, Giegling I, et al. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. Int J Neuropsychopharmacol. 2008; 11(2): 217-228.
38. Sacher J, Wilson AA, Houle S, et al. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry. 2010; 67(5): 468-474.
39. Keating C, Tilbrook A, Kulkarni J. Oestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response? Int J Neuropsychopharmacol. 2011; 14(4): 553-566.
40. Meyers B, D'Agostino A, Walker J, Kritzer MF. Gonadectomy and hormone replacement exert region-and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience. 2010; 165(3): 850-862.
41. Wu JB, Chen K, Li Y, Lau YF, Shih JC. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 2009; 23(11): 4029-4038.
42. Schwartz TL. Introduction to the special issue focused on the future or psychopharmacological practice. Clinical Neuropsychiatry. 2011; 8(1): 3.
43. Garriock HA, Moreno FA. Genetics of depression: implications for clinical practice yet? Clinical Neuropsychiatry. 2011; 8(1): 37-46.
44. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005; 95(4): 434-441.
45. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008; 13(10): 855-870.
46. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010; 2(3): 326-331.